Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/14595
Title: In vitro expression studies of non structural 1 protein of Canine Parvo virus 2 by polyclonal antiserum raised against CPV2-NS1 protein expressed in Escherichia coli as an antigen
Authors: Kumar, G Ravi
Saxena, Shikha
Saxena, Lovleen
Chaturvedi, Uttara
Santra, Lakshman
Kumar, Rajiv
Sahoo, Aditya Prasad
Rajmani
Kumar, Aswani
Desai, G S
Kumar, Sudesh
Tiwari, Ashok K
Keywords: Canine Parvo virus;NS1 gene;Polyclonal sera;Prokaryotic expression
Issue Date: Sep-2012
Publisher: NISCAIR-CSIR, India
Abstract: The canine Parvovirus 2, non-structural 1(NS1) is a novel candidate tumor suppressor gene. To confirm the expression of the NS1 in HeLa cells after transfection there was a need to raise antiserum against CPV2- NS1. Therefore, this study was carried out to express and purify the recombinant NS1(rNS1), and characterize the polyclonal serum. CPV2-NS1, complete coding sequence (CDS) was amplified, cloned in pET32a+ and expressed in BL21 (DE3) (pLysS). SDS–PAGE analysis revealed that the expression of the recombinant protein was maximum when induced with 1.5 mM IPTG. The 6 × His tagged fusion protein was purified on Ni-NTA resin under denaturing conditions and confirmed by western blot using CPV2 specific antiserum. The rabbits were immunized with the purified rNS1 to raise anti-NS1 polyclonal antiserum. The polyclonal serum was tested for specificity and used for confirming the expression of NS1 in HeLa transfected with pcDNA.cpv2.ns1 by indirect fluorescent antibody test (IFAT), flow cytometry and western blot. The polyclonal antiserum against NS1 could be very useful to establish functional in vitro assays to explore role of NS1 in cancer therapeutics.
Page(s): 618-624
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.50(09) [September 2012]

Files in This Item:
File Description SizeFormat 
IJEB 50(9) 618-624.pdf443.07 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.